Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.53 |
| ▸ | DRD4 | P21917 | 5/20 | 0.53 |
| ▸ | DRD3 | P35462 | 5/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.51 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.43 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3070233 | 0.88 | DRD2 (0.56) | DRD2DRD4DRD3HRH3HTR2A | |
| SCHEMBL3070986 | 0.84 | HRH3 (0.58) | DRD2DRD4DRD3HRH3HTR2A | |
| SCHEMBL3082257 | 0.84 | HRH3 (0.70) | DRD2DRD4DRD3HRH3HTR2A | |
| SCHEMBL3072333 | 0.77 | HRH3 (0.54) | DRD2DRD4DRD3HRH3HTR2A | |
| SCHEMBL3070959 | 0.76 | HRH3 (0.55) | DRD2HRH3HTR2AHRH1ABCB1 | |
| SCHEMBL5188091 | 0.76 | PRMT5 (0.44) | GRM2S1PR5 | |
| SCHEMBL4639757 | 0.73 | MEN1 (0.52) | DRD2DRD4DRD3MEN1KMT2A | |
| SCHEMBL3065720 | 0.72 | HRH3 (0.59) | DRD2DRD4DRD3HRH3HTR2A | |
| SCHEMBL3084148 | 0.72 | HRH3 (0.55) | DRD2DRD4DRD3HRH3HTR2A | |
| SCHEMBL4270619 | 0.72 | KDM4E (0.49) | DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275046-A1 | Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2008-11-06 | — | — | US | claimed |
| US-7790720-B2 | Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses | UCB PHARMA, S.A. (BE) | 2010-09-07 | — | — | US | disclosed |
| US-20080275046-A1 | Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275046-A1 | Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses | OXER1, OXTR, OGFR | DRD2 930/4885DRD4 863/4885DRD3 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.